SCHEMBL4069321

SCHEMBL4069321

CCCCNC(=O)N(Cc1ccc2c(c1)OCO2)Cc1cc2cc(C)cc(C)c2[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.53
POLB P06746 4/20 0.53
MAPT P10636 4/20 0.53
HPGD P15428 3/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
ALDH1A1 P00352 9/20 0.51
NPSR1 Q6W5P4 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD17B10 Q99714 6/20 0.51
TSHR P16473 4/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ALOX15 P16050 3/20 0.51
HTT P42858 2/20 0.51
CASP1 P29466 1/20 0.51
FYN P06241 1/20 0.50
PKM P14618 1/20 0.49
ALOX12 P18054 1/20 0.49
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073864 0.95 KDM4E (0.55) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4079794 0.93 ALDH1A1 (0.53) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL5456265 0.92 POLB (0.59) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4080208 0.91 KDM4E (0.56) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4079586 0.91 KDM4E (0.51) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4074168 0.91 KDM4E (0.49) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4075906 0.87 PKM (0.58) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4077411 0.87 ALDH1A1 (0.53) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4077438 0.87 KDM4E (0.54) KDM4EPOLBMAPTHPGDUSP2
SCHEMBL4072295 0.86 KDM4E (0.55) KDM4EPOLBMAPTHPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885POLB 315/4885MAPT 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.